Syndax Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Public

  • Employees
  • 298

Employees

  • Stock Symbol
  • SNDX

Stock Symbol

  • Share Price
  • $8.72
  • (As of Friday Closing)

Syndax General Information

Description

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Contact Information

Website
www.syndax.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 35 Gatehouse Drive
  • Building D, Floor 3
  • Waltham, MA 02451
  • United States
+1 (781)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 35 Gatehouse Drive
  • Building D, Floor 3
  • Waltham, MA 02451
  • United States
+1 (781)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Syndax Stock Performance

As of 20-Nov-2026, Syndax’s stock price is $8.72. Its current market cap is $785M with 90M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.72 $9.13 $8.41 - $25.59 $785M 90M 2.61M -$2.37

Syndax Financials Summary

As of 30-Sep-2026, Syndax has a trailing 12-month revenue of $290M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,376,281 1,391,623 739,675 1,471,052
Revenue 289,678 172,352 23,680 0
EBITDA (179,600) (274,361) (339,911) (230,303)
Net Income (209,483) (285,422) (318,758) (209,360)
Total Assets 692,671 529,706 724,816 612,880
Total Debt 245,320 1,523 14,174 1,635
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Syndax Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Syndax‘s full profile, request access.

Request a free trial

Syndax Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Syndax‘s full profile, request access.

Request a free trial

Syndax Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination
Drug Discovery
Waltham, MA
298 As of 2025

Boston, MA
 

Lexington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Syndax Competitors (115)

One of Syndax’s 115 competitors is Aura Biosciences, a Formerly VC-backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aura Biosciences Formerly VC-backed Boston, MA
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA
Imunon Corporation Lawrenceville, NJ
AB Science Formerly Accelerator/Incubator backed Paris, France
Agios Pharmaceuticals Formerly VC-backed Cambridge, MA
You’re viewing 5 of 115 competitors. Get the full list »

Syndax Patents

Syndax Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026183535-A1 Aryl ether analogs comprising an ether link as inhibitors of the menin-mll interaction Pending 27-Feb-2025
WO-2026183524-A1 Benzamide aryl ether analogs comprising a 4,5-spiro ring system as inhibitors of the menin-mll interaction Pending 27-Feb-2025
WO-2026183418-A1 Benzamide aryl ether analogs comprising a direct link as inhibitors of the menin-mll interaction Pending 27-Feb-2025
US-20260258053-A1 Benzamide aryl ether analogs comprising an amine linker as inhibitors of the menin-mll interaction Pending 27-Feb-2025
WO-2026183529-A1 Benzamide aryl ether analogs comprising an amine linker as inhibitors of the menin-mll interaction Pending 27-Feb-2025 C07D403/14
To view Syndax’s complete patent history, request access »

Syndax Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Syndax ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

32.34 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Syndax’s complete esg history, request access »

Syndax FAQs

  • When was Syndax founded?

    Syndax was founded in 2005.

  • Where is Syndax headquartered?

    Syndax is headquartered in Waltham, MA.

  • What is the size of Syndax?

    Syndax has 298 total employees.

  • What industry is Syndax in?

    Syndax’s primary industry is Drug Discovery.

  • Is Syndax a private or public company?

    Syndax is a Public company.

  • What is Syndax’s stock symbol?

    The ticker symbol for Syndax is SNDX.

  • What is the current stock price of Syndax?

    As of 20-Nov-2026 the stock price of Syndax is $8.72.

  • What is the current market cap of Syndax?

    The current market capitalization of Syndax is $785M.

  • What is Syndax’s current revenue?

    The trailing twelve month revenue for Syndax is $290M.

  • Who are Syndax’s competitors?

    Aura Biosciences, Dicerna Pharmaceuticals, Imunon, AB Science, and Agios Pharmaceuticals are some of the 115 competitors of Syndax.

  • What is Syndax’s annual earnings per share (EPS)?

    Syndax’s EPS for 12 months was -$2.37.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process